EGFR-to-Src family tyrosine kinase switching in proliferating-DTP TNBC cells creates a hyperphosphorylation-dependent

Nazia Chaudhary1, Bhagya Shree Choudhary1,2, Anusha Shivashankar1

  • 1Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Centre, Navi-Mumbai, Maharashtra, India.

Cancer Cell International
|February 19, 2025
PubMed

Insights

Triple-Negative Breast Cancer (TNBC) cells develop drug resistance. This study reveals a hyper-phosphorylation state in resistant TNBC cells, involving EGFR and Src kinases, creating a vulnerability to EGFR inhibitors.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Triple-Negative Breast Cancer (TNBC) is aggressive, with limited treatment options and poor outcomes.
  • Chemotherapy resistance and residual disease are major challenges in TNBC management.
  • Molecular mechanisms driving proliferation in chemo-resistant TNBC cells remain poorly understood.

Purpose of the Study:

  • To establish clinically relevant cellular models of chemo-resistant TNBC.
  • To investigate the molecular mechanisms of proliferation in drug-tolerant persister (PDTP) cells.
  • To identify potential therapeutic vulnerabilities in residual TNBC.

Main Methods:

  • Established TNBC subtype-specific PDTP cellular models.
  • Analyzed phospho-tyrosine signaling using mass spectrometry.
  • Investigated protein expression, localization, and kinase activity (EGFR, Src family kinases, NDRG1, STAT3, AKT, MAP kinases).
  • Assessed sensitivity to EGFR tyrosine kinase inhibitors (TKIs) in combination with chemotherapy.

Main Results:

  • TNBC PDTPs exhibit enhanced phospho-tyrosine content compared to parental cells.
  • EGFR expression is decreased but hyper-phosphorylated in PDTPs.
  • Increased lysosomal trafficking of EGFR mediated by NDRG1 was observed.
  • A hyper-activated EGFR-Src kinase axis was identified, leading to downstream signaling over-activation.
  • Paclitaxel-derived PDTPs showed sensitivity to Gefitinib, a EGFR TKI.

Conclusions:

  • TNBC PDTPs develop a unique hyper-phosphorylation state driven by an EGFR-Src tyrosine kinase switch.
  • This altered signaling creates a vulnerability exploitable by EGFR TKIs.
  • Targeting the EGFR-Src axis offers a potential therapeutic strategy for chemo-resistant TNBC.

Related Concept Videos

Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
12.1K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
Enzyme-linked Receptors01:00

Enzyme-linked Receptors

Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
77.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.7K
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
6.1K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.3K